Top

Outcomes of Allogeneic HCT in patients with Hodgkin Lymphoma in the era of Checkpoint Inhibitors: A joint CIBMTR and EBMT analysis.

Lymphoma Working Party (LWP)
Study type:
Retrospective Studies
Study number:
2020-R-03
Type of treatment:
Allogeneic
Diseases:
Hodgkin’s Disease (HD)
Short title:
Allo HSCT For HL in the era of Checkpoint Inhibitors
Primary objective:
 
Key inclusion criteria:
 
Country:
 
Principal investigator:
Miguel-Angel Perales
EBMT Study coordinator:
Hervé Finel
Study coordinator email:
herve.finel@upmc.fr